- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07410117
REGN7508 chez les participants adultes pour la prévention de la thrombose associée au cancer (ROXI-CAT-I)
Étude de phase 3, multicentrique, randomisée, en double aveugle, contrôlée par placebo, visant à évaluer l'efficacité et l'innocuité du REGN7508, un anticorps monoclonal anti-FXI, pour la prophylaxie primaire de la thrombose associée au cancer chez des participants atteints de tumeurs solides suivant un traitement anticancéreux (ROXI-CAT-I)
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Clinical Trials Administrator
- Numéro de téléphone: 844-734-6643
- E-mail: clinicaltrials@regeneron.com
Lieux d'étude
-
-
-
Tbilisi, Géorgie, 0159
- Recrutement
- Institute of Clinical Oncology
-
Tbilisi, Géorgie, 0186
- Recrutement
- Caucasus Medical Centre
-
Tbilisi, Géorgie, 0144
- Recrutement
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Tbilisi, Géorgie, 0179
- Recrutement
- LTD Cancer Research Centre
-
Tbilisi, Géorgie, 0179
- Recrutement
- JSC Evex Hospitals - Caraps Medline
-
Tbilisi, Géorgie, 0102
- Recrutement
- American Hospital Tbilisi
-
Tbilisi, Géorgie, 0112
- Recrutement
- Llc Todua Clinic
-
Tbilisi, Géorgie, 0112
- Recrutement
- Israel Georgia Medical Research Clinic Helsicore
-
-
Adjara
-
Batumi, Adjara, Géorgie, 6000
- Recrutement
- LTD High Technology Hospital Medcenter
-
-
Imereti
-
Kutaisi, Imereti, Géorgie, 4600
- Recrutement
- Krystyna Kiel Oncology Center
-
-
-
-
-
Niigata, Japon, 951-8520
- Recrutement
- Niigata University Medical & Dental Hospital
-
-
Ehime
-
Tōon, Ehime, Japon, 791-0295
- Recrutement
- Ehime University Hospital
-
-
Gunma
-
Ōta, Gunma, Japon, 373-8550
- Recrutement
- Gunma Prefectural Cancer Center
-
-
Hyōgo
-
Akashi, Hyōgo, Japon, 673-8558
- Recrutement
- Hyogo Cancer Center
-
-
Kagawa-ken
-
Kita-gun, Kagawa-ken, Japon, 761-0793
- Recrutement
- Kagawa University Hospital
-
-
Kanagawa
-
Isehara-Shi, Kanagawa, Japon, 259-1193
- Recrutement
- Tokai University Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japon, 602-8566
- Recrutement
- University Hospital Kyoto Prefectural University of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japon, 980-8574
- Recrutement
- Tohoku University Hospital
-
-
Osaka
-
Chuo, Osaka, Japon, 540-0006
- Recrutement
- National Hospital Organization Osaka National Hospital (ONH)
-
-
Saitama
-
Ina-machi, Saitama, Japon, 362-0806
- Recrutement
- Saitama Cancer Center
-
-
Tokyo
-
Chuo Ku, Tokyo, Japon, 104-0045
- Recrutement
- National Cancer Center Hospital - Tsukiji Campus
-
Shinjuku, Tokyo, Japon, 160-0023
- Recrutement
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube, Yamaguchi, Japon, 755-8505
- Recrutement
- Yamaguchi University Hospital
-
-
-
-
Florida
-
Hialeah, Florida, États-Unis, 33013
- Recrutement
- Bioresearch Partner- Hialeah Hospital
-
North Miami Beach, Florida, États-Unis, 33169
- Recrutement
- Helios Clinical Research
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Beth Israel Deaconess Medical Center
-
-
New York
-
New York, New York, États-Unis, 10021
- Recrutement
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso, Texas, États-Unis, 79902
- Retiré
- El Paso Medical Research Institute (Medresearch Inc)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Key Exclusion Criteria:
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
|
Administered per the protocol |
|
Expérimental: REGN7508
|
Administered per the protocol
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Délai jusqu'au premier événement de saignement majeur selon les critères de la Société Internationale de Thrombose et d'Hémorragie (ISTH) ou de saignement cliniquement pertinent non majeur (CRNM) centralement validés
Délai: Sur une période de 6 mois
|
Sur une période de 6 mois
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Délai: Through 6 months
|
Through 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Occurrence des événements indésirables émergents du traitement (TEAE)
Délai: Jusqu'au jour 245
|
Jusqu'au jour 245
|
|
Sévérité des TEAEs
Délai: Jusqu'au jour 245
|
Jusqu'au jour 245
|
|
Amplitude des ADA pour REGN7508
Délai: Jusqu'au jour 245
|
Jusqu'au jour 245
|
|
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic VTE
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic DVT
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic non-fatal PE
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of thromboembolism-related death
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental VTE
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE-related death
Délai: Through 6 months
|
Through 6 months
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Délai: Through 6 months
|
Through 6 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Délai: Up to day 245
|
Up to day 245
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Trial Management, Regeneron Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies des voies respiratoires
- Maladies pulmonaires
- Embolie et thrombose
- Embolie
- Thromboembolie
- Thrombose
- Conditions pathologiques, signes et symptômes
- Tumeurs
- Embolie pulmonaire
- La thrombose veineuse
- Hémorragie
- Thromboembolie veineuse
Autres numéros d'identification d'étude
- R7508-CAT-2392
- 2024-519298-21-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Délai de partage IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Critères d'accès au partage IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .